Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
Brian B GodmanMainul HaqueSantosh KumarMd Salequl IslamJaykaran CharanS M Mahbubur RashidAmanj Baker KurdiEleonora AllocatiMuhammed Abu BakarMd Saghir Abdur RahimNusrat SultanaFarzana DeebaM A Halim KhanA B M Muksudul AlamIffat JahanZubair Mahmood KamalHumaira Hasinnull Munzur-E-MurshidShamsun NaharMonami HaqueSiddhartha DuttaJha Pallavi AbhayanandRimple Jeet KaurJitendra AcharyaTakuma SugaharaHye-Young KwonSeung Jin BaeKaren Koh Pek KhuanTanveer Ahmed KhanShahzad HussainZikria SaleemAlice PisanaJanney WaleMihajlo Michael JakovljevicPublished in: Current medical research and opinion (2021)
Increasing use of long-acting insulin analogues across countries is welcomed, adding to the range of insulins available, which increasingly includes biosimilars. A number of activities are needed to enhance the use of long-acting insulin analogue biosimilars in Japan, Korea and Pakistan.